Key clinical point: Breast-conserving therapy (BCT) vs mastectomy resulted in higher improvement in survival without increasing the risk for locoregional recurrence (LRR) in patients with breast cancer (BC), regardless of their clinical nodal status.
Major finding: BCT vs mastectomy improved overall survival (hazard ratio [HR] 1.37; P < .001, and HR 1.46; P < .001, respectively) and BC-specific survival (HR 1.32; P < .001, and HR 1.44; P = .008, respectively) without increasing the risk for LRR (P = .14 and P = .70, respectively) in patients with clinical node-negative and node-positive BC.
Study details: Findings are from an analysis including 13,914 women with T1-3N0-3 BC (clinically node-negative BC n = 12,537 and clinically node-positive BC n = 1,377) from a prospectively maintained database, the majority of whom received systemic therapy.
Disclosures: This study did not declare the source of funding. The authors did not report any conflicts of interest.
Source: Vasilyeva E et al. Breast-conserving therapy is associated with improved survival without an increased risk of locoregional recurrence compared with mastectomy in both clinically node-positive and node-negative breast cancer patients. Ann Surg Oncol. 2023 (Jun 26). Doi: 10.1245/s10434-023-13784-x